Back on the scene: Advances and challenges in CD3-related drugs in tumor therapy

Han Deng; Zhendong Niu; Zhixiong Zhang; Jixuan Zhang; Guan Wang; Yuxi Wang; Jinliang Yang

doi:10.1016/j.drudis.2022.04.019

Back on the scene: Advances and challenges in CD3-related drugs in tumor therapy

Drug Discov Today. 2022 Aug;27(8):2199-2208. doi: 10.1016/j.drudis.2022.04.019. Epub 2022 Apr 27.

Authors

Han Deng¹, Zhendong Niu², Zhixiong Zhang¹, Jixuan Zhang³, Guan Wang⁴, Yuxi Wang⁵, Jinliang Yang⁴

Affiliations

¹ State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China; Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
² Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
³ Office of Supervision, Sichuan Development Holding Co., Ltd, Chengdu, China.
⁴ State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China.
⁵ State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China; Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Electronic address: yuxiwang@scu.edu.cn.

PMID: 35489674
DOI: 10.1016/j.drudis.2022.04.019

Abstract

CD3 molecules are mainly distributed on the membrane of mature T cells. They are involved in T cell antigen recognition, signal transduction, and regulation of T cell development. CD3-related monoclonal antibodies (mAbs) are mainly used in the treatment of autoimmune diseases. Nearly half of all bispecific antibodies developed are used in tumor therapy, one of which is CD3 antigen. In this review, we discuss the importance of biological function and the crucial role of CD3 in tumor therapy. We highlight the research status of antibodies and small molecules targeting CD3 to provide guidance for future drug research.

Keywords: Antibody; CD3; TCR/CD3 complex.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
CD3 Complex
Humans
Lymphocyte Activation*
Neoplasms* / drug therapy
T-Lymphocytes

Substances

Antibodies, Monoclonal
CD3 Complex